RxDoctor Payments Data

Lilia Myrna Rasul

Nurse Practitioner · Tomball, TXNPI 1255846473

Payments from drug & device makers

$2,909in general payments, 2019–2025

Across 132 payments — averaging $22.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$732
  • Amarin Pharma, Inc.$253
  • AstraZeneca$213
  • Exact Sciences$198
  • Eisai Inc.$137
  • Amgen$135
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$2,80196%
  • Education$1094%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,909 in reported general payments places this provider in the 85th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$21,301
Medicare patients
80
Services billed
489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$53,049
JanuviaSitagliptin Phosphate17$17,830
JardianceEmpagliflozin16$11,740
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,432
Rosuvastatin Calcium134$3,178
ShingrixVaricella-Zoster Ge/As01b/Pf14$3,056
Atorvastatin Calcium267$2,870
MyrbetriqMirabegron12$2,679
Nifedipine ErNifedipine51$1,455
Lisinopril151$1,450
Gabapentin58$1,420
Amlodipine Besylate144$1,089
Losartan Potassium76$1,008
Levothyroxine Sodium101$866
Nano 2nd Gen Pen NeedlePen Needle, Diabetic14$752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$732$53,04936 claims
MerckJanuvia$57$17,83017 claims
GSKTrelegy Ellipta, Shingrix$87$12,48829 claims
Astellas Pharma US IncMyrbetriq$114$2,67912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Tomball

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →